Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905903 · ClinicalTrials.gov registry record · NA
An In Vivo Model for Postinflammatory Hyperpigmentation
A NA study of Post-inflammatory Hyperpigmentation, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02905903: Completed NA study of Post-inflammatory Hyperpigmentation, sponsored by Henry Ford Health System.
NCT02905903 is a NA study of Post-inflammatory Hyperpigmentation that has completed, run by Henry Ford Health System. The registered enrollment target is 30 participants, above the 18-participant average among 3 other Post-inflammatory Hyperpigmentation trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02905903, a NA study of Post-inflammatory Hyperpigmentation, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that occurs after cutaneous inflammation or injury that frequently affects darker skinned populations. Previously, a model of 35% TCA-induced PIH was validated against acne induced PIH, which has value in product testing for the treatment of PIH. In this second phase of the study, the investigators would like to determine if a lower concentration of TCA-induced PIH is comparable to acne-induced PIH.
Primary Outcome
This will be determined by comparing acne induced PIH and the different concentrations of TCA induced PIH
Conditions Studied
Interventions
- DRUG Tricholoacetic Acid (TCA)
Study Locations (1)
Michigan
- Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard, - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-02-14 |
| Est. Completion | 2019-06-21 |
| Phase | NA |
What the finished NCT02905903 record still lists
NCT02905903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, above the 18-participant average among 3 other Post-inflammatory Hyperpigmentation trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Post-inflammatory Hyperpigmentation appearing as the primary indexed condition, and to 1 intervention - of which Tricholoacetic Acid (TCA) is the first listed.
NCT02905903 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02905903 about?
NCT02905903 is a clinical study titled "An In Vivo Model for Postinflammatory Hyperpigmentation". Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that occurs after cutaneous inflammation or injury that frequently affects darker skinned populations. Previously, a model of 35% TCA-induced PIH was validated against acne induced PIH, which has value in product testing for the...
What is the current status of trial NCT02905903?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-02-14. Estimated completion is 2019-06-21.
What conditions does trial NCT02905903 study?
This clinical trial studies the following conditions: Post-inflammatory Hyperpigmentation.
What interventions are being tested in trial NCT02905903?
The interventions under investigation include: Tricholoacetic Acid (TCA) (DRUG).
Who is sponsoring clinical trial NCT02905903?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02905903 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-inflammatory Hyperpigmentation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
COMPLETED · NA
-
A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color
COMPLETED · NA
-
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI